Oxetanyl Sulfoxide MMS-350 Ameliorates Pulmonary Fibrosis In Vitro, In Vivo, and Ex Vivo.

Abstract

Fibrosis is a common feature of several diseases, involves different organs, and results in significant morbidity and mortality. There are currently no effective therapies to halt the progression of fibrosis or reverse it. We have identified the highly water-soluble MMS-350, a novel bis-oxetanyl sulfoxide, as an antifibrotic agent. MMS-350 reduced the profibrotic phenotype induced in vitro in primary human fibroblasts and ameliorated bleomycin-induced pulmonary fibrosis in vivo. Furthermore, MMS-350 reversed fibrosis in human skin in organ culture. MMS-350 reduced levels of extracellular matrix proteins, the activation of fibroblasts, and the induction of pro-fibrotic factors. Similar effects at lower concentrations were observed with KRL507-031 and CL-613-091, two more lipophilic MMS-350 analogues. The fact that MMS-350 was effective at reducing pulmonary fibrosis induced by different triggers, the differential biological effects of its close structural analogues and its oral availability make it an attractive therapeutic candidate for organ fibrosis.

• Authors: Logan Mlakar, Jessica Lane, Takahisa Takihara, Chaemin Lim, Melissa M Sprachman, Kayla R Lloyd, Peter Wipf, Carol Feghali-Bostwick
• Journal: ACS medicinal chemistry letters (ACS Med Chem Lett) Vol. 11 Issue 11 Pg. 2312-2317 (Nov 12 2020) ISSN: 1948-5875 [Print] United States
• PMID: 33214846 (Publication Type: Journal Article)